Literature DB >> 20074261

The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia.

A M Lynch1, J R Murphy, R S Gibbs, R J Levine, P C Giclas, J E Salmon, V M Holers.   

Abstract

OBJECTIVE: To determine the interrelationships during early pregnancy of complement-activation fragments Bb, C3a and sC5b-9, and angiogenesis-related factors placental growth factor (PiGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), and their associations with pre-eclampsia.
DESIGN: Prospective cohort study.
SETTING: Denver complement study (June 2005-June 2008). POPULATION: A total of 668 pregnant women with singleton gestations, recruited between 10 and 15 weeks of gestation.
METHODS: Using univariable and multivariable logistic regression analysis, concentrations of complement-activation fragments and angiogenesis-related factors were compared between 10 and 15 weeks of gestation in women who subsequently did or did not develop pre-eclampsia. Interrelationships between these variables were tested using the non-parametric Spearman rank correlation coefficient. MAIN OUTCOME MEASURE: Pre-eclampsia. The association of complement-activation fragments and angiogenesis-related factors with obesity was also examined.
RESULTS: The mean (+/-SD) levels of complement Bb in early pregnancy among women who did and did not develop pre-eclampsia were 0.84 (+/-0.26) microg/ml and 0.69 (+/-0.2) microg/ml, respectively (P = 0.001). Concentrations of PiGF were significantly (P = 0.01) lower (31 +/- 12 pg/ml) in early pregnancy in the pre-eclamptic group of women, as compared with the normotensive group (39 +/- 32 pg/ml). The adjusted odds ratio (AOR) of Bb and PiGF were 2.1 (CI = 1.4-3.1, P < 0.0003) and 0.2 (CI = 0.07-0.7, P = 0.01), respectively. There was no significant difference in the levels of C3a, sC5b-9, sFlt-1 and sEng in early pregnancy among women who developed pre-eclampsia, compared with women who remained normotensive during pregnancy. Higher levels of Bb (P = 0.0001) and C3a (P = 0.03), and lower levels of sFlt-1 (P = 0.0002) and sEng (P = 0.0001) were found among women with obesity, compared with non-obese controls. No meaningful relationships were found between the complement-activation fragments and the angiogenesis-related factors.
CONCLUSIONS: In this cohort during early pregnancy, increased concentrations of complement-activation factor Bb and lower concentrations of PiGF were associated with the development of pre-eclampsia later in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20074261      PMCID: PMC5267351          DOI: 10.1111/j.1471-0528.2009.02473.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  37 in total

Review 1.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  The role of complement in inflammatory diseases from behind the scenes into the spotlight.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

Review 3.  Pre-eclampsia: Is the immune maladaptation hypothesis still standing? An epidemiological update.

Authors:  Gus Dekker; Pierre-Yves Robillard
Journal:  J Reprod Immunol       Date:  2007-05-09       Impact factor: 4.054

4.  Immune activation early in pregnancy: trouble down the road?

Authors:  Robert M Silver
Journal:  Am J Obstet Gynecol       Date:  2008-10       Impact factor: 8.661

Review 5.  Fetal-maternal conflict, trophoblast invasion, preeclampsia, and the red queen.

Authors:  Robert Pijnenborg; Lisbeth Vercruysse; Myriam Hanssens
Journal:  Hypertens Pregnancy       Date:  2008       Impact factor: 2.108

6.  Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance.

Authors:  Jinhui Zhang; Wendy Wright; David A Bernlohr; Samuel W Cushman; Xiaoli Chen
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-01-23       Impact factor: 4.310

7.  Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia.

Authors:  S C Tidwell; H N Ho; W H Chiu; R J Torry; D S Torry
Journal:  Am J Obstet Gynecol       Date:  2001-05       Impact factor: 8.661

8.  Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.

Authors:  Sarosh Rana; S Ananth Karumanchi; Richard J Levine; Shivalingappa Venkatesha; Jose Alejandro Rauh-Hain; Hector Tamez; Ravi Thadhani
Journal:  Hypertension       Date:  2007-05-21       Impact factor: 10.190

9.  Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia.

Authors:  Anne M Lynch; James R Murphy; Tim Byers; Ronald S Gibbs; Margaret C Neville; Patricia C Giclas; Jane E Salmon; V Michael Holers
Journal:  Am J Obstet Gynecol       Date:  2008-01-25       Impact factor: 8.661

10.  Complement abnormalities in acquired lipodystrophy revisited.

Authors:  David B Savage; Robert K Semple; Menna R Clatworthy; Paul A Lyons; B Paul Morgan; Elaine K Cochran; Phillip Gorden; Philippa Raymond-Barker; Peter R Murgatroyd; Claire Adams; Ian Scobie; Ghulam J Mufti; Graeme J M Alexander; Sathia Thiru; Incoronata Murano; Saverio Cinti; Afzal N Chaudhry; Kenneth G C Smith; Stephen O'Rahilly
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

View more
  24 in total

1.  Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus.

Authors:  Jill P Buyon; Mimi Y Kim; Marta M Guerra; Sifan Lu; Emily Reeves; Michelle Petri; Carl A Laskin; Michael D Lockshin; Lisa R Sammaritano; D Ware Branch; T Flint Porter; Allen Sawitzke; Joan T Merrill; Mary D Stephenson; Elisabeth Cohn; Jane E Salmon
Journal:  Clin J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 8.237

2.  Maternal and fetal alternative complement pathway activation in early severe preeclampsia.

Authors:  M Camille Hoffman; Kristen K Rumer; Anita Kramer; Anne M Lynch; Virginia D Winn
Journal:  Am J Reprod Immunol       Date:  2013-10-16       Impact factor: 3.886

3.  The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia.

Authors:  Anne M Lynch; Brandie D Wagner; Patricia C Giclas; Nancy A West; Ronald S Gibbs; V Michael Holers
Journal:  Am J Reprod Immunol       Date:  2015-10-29       Impact factor: 3.886

4.  Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.

Authors:  Eleazar Soto; Roberto Romero; Juan Pedro Kusanovic; Giovanna Ogge; Youssef Hussein; Lami Yeo; Sonia S Hassan; Chong Jai Kim; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-25

Review 5.  Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

Authors:  A M Lynch; J E Salmon
Journal:  Placenta       Date:  2010-04-27       Impact factor: 3.481

6.  Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes.

Authors:  Anne M Lynch; Ronald S Gibbs; James R Murphy; Patricia C Giclas; Jane E Salmon; V Michael Holers
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

7.  Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia.

Authors:  A Halmos; J Rigó; J Szijártó; G Füst; Z Prohászka; A Molvarec
Journal:  Clin Exp Immunol       Date:  2012-07       Impact factor: 4.330

8.  Complement factor B activation in patients with preeclampsia.

Authors:  Ivan Velickovic; Mudar Dalloul; Karen A Wong; Olufunke Bakare; Franz Schweis; Maya Garala; Amit Alam; Giorgio Medranda; Jovana Lekovic; Waqas Shuaib; Andreas Tedjasukmana; Perry Little; Daniel Hanono; Ruvini Wijetilaka; Jeremy Weedon; Jun Lin; Roulhac d'Arby Toledano; Ming Zhang
Journal:  J Reprod Immunol       Date:  2015-01-03       Impact factor: 4.054

9.  Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.

Authors:  Mimi Y Kim; Marta M Guerra; Elianna Kaplowitz; Carl A Laskin; Michelle Petri; D Ware Branch; Michael D Lockshin; Lisa R Sammaritano; Joan T Merrill; T Flint Porter; Allen Sawitzke; Anne M Lynch; Jill P Buyon; Jane E Salmon
Journal:  Ann Rheum Dis       Date:  2018-01-25       Impact factor: 19.103

Review 10.  Angiogenic factors and preeclampsia.

Authors:  Sharon E Maynard; S Ananth Karumanchi
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.